FOXP3 and neoplasm: In summary, our data suggest that targeting FoxP3 through small molecules may be a therapeutic strategy to inhibit Tregs in the TME and enhance anti-tumor responses potently, implying potential application in patients as a stand-alone treatment or in combination with other therapies.